Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05802056 · ClinicalTrials.gov registry record · Phase 1

Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis

A Phase 1 study of Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, sponsored by Mayo Clinic.

Recruiting
Registry status
Phase 1
Development phase
15
Enrollment target
1
Study location

NCT05802056 is a Phase 1 study of Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 15 participants, below the 245-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05802056, a Phase 1 study of Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
Phase 1
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

This phase Ib trial test effects of aldesleukin in combination with nivolumab and standard chemotherapy in treating patients with gastric cancer that has spread to the tissue lining of the abdomen (peritoneal metastasis). Aldesleukin is similar to a protein that naturally exists in the body that stimulates the immune system to fight infections. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as leucovorin calcium, fluorouracil, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving aldesleukin in combination with nivolumab and standard chemotherapy may work better in treating patients with gastric cancer with peritoneal metastasis.

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Biopsy
  • PROCEDURE Diagnostic Laparoscopy
  • BIOLOGICAL Aldesleukin

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2023-11-29
Est. Completion 2030-04-15
Phase Phase 1

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT05802056

The ClinicalTrials.gov registry entry for NCT05802056 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 245-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (94% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Gastric Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT05802056 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT05802056 about?

NCT05802056 is a clinical study titled "Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis". This phase Ib trial test effects of aldesleukin in combination with nivolumab and standard chemotherapy in treating patients with gastric cancer that has spread to the tissue lining of the abdomen (peritoneal metastasis). Aldesleukin is similar to a protein that naturally exists in the body that sti...

What is the current status of trial NCT05802056?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2023-11-29. Estimated completion is 2030-04-15.

What conditions does trial NCT05802056 study?

This clinical trial studies the following conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Clinical Stage IV Gastric Cancer AJCC v8, Metastatic Malignant Neoplasm in the Peritoneum, Metastatic Gastric Carcinoma.

What interventions are being tested in trial NCT05802056?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy (PROCEDURE), Diagnostic Laparoscopy (PROCEDURE), Aldesleukin (BIOLOGICAL).

Who is sponsoring clinical trial NCT05802056?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05802056 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gastric Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.